In his paper, Josh D. Woolley, MD, PhD, proposes multidrug active placebos and limited disclosure to finally mask high-dose psilocybin trials.
Josh D. Woolley, MD, PhD
Advertisement
Josh D. Woolley, MD, PhD, professor of psychiatry and behavioral sciences, University of California, San Francisco.
Articles by Josh D. Woolley, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
2
FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
3
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
4
Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest
5